1. The median overall survival for patients receiving177Lu-Dotatate and intramuscular, long-acting octreotide was 47.0 months and 36.3 months respectively 2. ...
1. 177Lu-Dotatate, a radiolabeled somatostatin analogue, was associated with increased progression-free survival and decreased overall mortality compared to standard therapy ...
Image: CC/Wiki 1. High pre- and post-operative levels of pancreastatin were significantly correlated with shorter progression free survival (PFS) and ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
